Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Bristol-Myers Squibb Company is a drug manufacturers-general business based in the US. Bristol-Myers Squibb Company shares (BMY) are listed on the NYSE and all prices are listed in US Dollars. Bristol-Myers Squibb Company employs 30,250 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$60.63|
|52-week range||$55.19 - $69.75|
|50-day moving average||$66.66|
|200-day moving average||$65.30|
|Wall St. target price||$80.24|
|Dividend yield||$1.92 (3.14%)|
|Earnings per share (TTM)||$-2.26|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-16)||-0.98%|
|1 month (2021-08-24)||-11.51%|
|3 months (2021-06-24)||-7.93%|
|6 months (2021-03-24)||-2.68%|
|1 year (2020-09-24)||4.09%|
|2 years (2019-09-24)||21.24%|
|3 years (2018-09-24)||61.59|
|5 years (2016-09-23)||7.35%|
Valuing Bristol-Myers Squibb Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bristol-Myers Squibb Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bristol-Myers Squibb Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 14.5784. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bristol-Myers Squibb Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Bristol-Myers Squibb Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $18.8 billion.
The EBITDA is a measure of a Bristol-Myers Squibb Company's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$44.4 billion|
|Operating margin TTM||18.55%|
|Gross profit TTM||$34 billion|
|Return on assets TTM||4.31%|
|Return on equity TTM||-11.76%|
|Market capitalisation||$136.2 billion|
TTM: trailing 12 months
There are currently 20.3 million Bristol-Myers Squibb Company shares held short by investors – that's known as Bristol-Myers Squibb Company's "short interest". This figure is 7.2% down from 21.9 million last month.
There are a few different ways that this level of interest in shorting Bristol-Myers Squibb Company shares can be evaluated.
Bristol-Myers Squibb Company's "short interest ratio" (SIR) is the quantity of Bristol-Myers Squibb Company shares currently shorted divided by the average quantity of Bristol-Myers Squibb Company shares traded daily (recently around 6.9 million). Bristol-Myers Squibb Company's SIR currently stands at 2.94. In other words for every 100,000 Bristol-Myers Squibb Company shares traded daily on the market, roughly 2940 shares are currently held short.
However Bristol-Myers Squibb Company's short interest can also be evaluated against the total number of Bristol-Myers Squibb Company shares, or, against the total number of tradable Bristol-Myers Squibb Company shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bristol-Myers Squibb Company's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Bristol-Myers Squibb Company shares in existence, roughly 10 shares are currently held short) or 0.0093% of the tradable shares (for every 100,000 tradable Bristol-Myers Squibb Company shares, roughly 9 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bristol-Myers Squibb Company.
Find out more about how you can short Bristol-Myers Squibb Company stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Bristol-Myers Squibb Company.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 29.16
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Bristol-Myers Squibb Company's overall score of 29.16 (as at 12/31/2018) is nothing to write home about – landing it in it in the 53rd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Bristol-Myers Squibb Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 3.83/100
Bristol-Myers Squibb Company's environmental score of 3.83 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb Company is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 18.82/100
Bristol-Myers Squibb Company's social score of 18.82 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol-Myers Squibb Company is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 14.02/100
Bristol-Myers Squibb Company's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Bristol-Myers Squibb Company is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Bristol-Myers Squibb Company scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Bristol-Myers Squibb Company has, for the most part, managed to keep its nose clean.
|Total ESG score||29.16|
|Total ESG percentile||52.58|
|Environmental score percentile||4|
|Social score percentile||4|
|Governance score percentile||4|
|Level of controversy||2|
Dividend payout ratio: 28.99% of net profits
Recently Bristol-Myers Squibb Company has paid out, on average, around 28.99% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.2% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Bristol-Myers Squibb Company shareholders could enjoy a 3.2% return on their shares, in the form of dividend payments. In Bristol-Myers Squibb Company's case, that would currently equate to about $1.92 per share.
While Bristol-Myers Squibb Company's payout ratio might seem fairly standard, it's worth remembering that Bristol-Myers Squibb Company may be investing much of the rest of its net profits in future growth.
Bristol-Myers Squibb Company's most recent dividend payout was on 31 October 2021. The latest dividend was paid out to all shareholders who bought their shares by 29 September 2021 (the "ex-dividend date").
Bristol-Myers Squibb Company's shares were split on a 1000000:95 basis on 6 August 2001. So if you had owned 95 shares the day before before the split, the next day you'd have owned 1000000 shares. This wouldn't directly have changed the overall worth of your Bristol-Myers Squibb Company shares – just the quantity. However, indirectly, the new 100% lower share price could have impacted the market appetite for Bristol-Myers Squibb Company shares which in turn could have impacted Bristol-Myers Squibb Company's share price.
Over the last 12 months, Bristol-Myers Squibb Company's shares have ranged in value from as little as $55.1871 up to $69.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Bristol-Myers Squibb Company's is 0.5879. This would suggest that Bristol-Myers Squibb Company's shares are less volatile than average (for this exchange).
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.
Everything we know about the Enfusion IPO, plus information on how to buy in.
Everything we know about the Intuity Medical IPO, plus information on how to buy in.
Everything we know about the Pyxis Oncology IPO, plus information on how to buy in.
Everything we know about the AEON Biopharma IPO, plus information on how to buy in.
Everything we know about the IHS Holding Ltd IPO, plus information on how to buy in.
Everything we know about the BT Brands IPO, plus information on how to buy in.
Everything we know about the Immix IPO, plus information on how to buy in.
Everything we know about the Keter Group SA IPO, plus information on how to buy in.
Everything we know about the Theseus Pharmaceuticals IPO, plus information on how to buy in.
Everything we know about the MiNK Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.